Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by LivaNova PLC

< Previous 1 2 3 Next >
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Present at the Jefferies Global Healthcare Conference
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Announce First-Quarter 2025 Results
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Present at the Barclays Global Healthcare Conference
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
From LivaNova PLC
Via Business Wire
Tickers LIVN
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Reports Third-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Appoints Susan Podlogar as a New Director
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Announce Third-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Present at the Baird Global Healthcare Conference
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Reports Second-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Announce Second-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Present at the Goldman Sachs Healthcare Conference
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Reports First-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova to Announce First-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
From LivaNova PLC
Via Business Wire
Tickers LIVN
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
From LivaNova PLC
Via Business Wire
Tickers LIVN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.